Cardiovascular Diabetology最新文献

{"title":"Beyond overweight, visceral adiposity is associated with estimation of cardiovascular risk in patients living with type 1 diabetes: findings from the SFDT1 cohort.","authors":"Laurence Salle, Jean-Baptiste Julla, Guy Fagherazzi, Pierre Gourdy, Erika Bezerra Parente, Hélène Hanaire, Sopio Tatulashvili, Emmanuel Disse, Sylvia Franc, Samy Hadjadj, Etienne Larger, Caroline Sanz, Patricia Vaduva, René Valero, Amélie Bonnefond, Emmanuel Cosson, Gloria A Aguayo, Jean-Pierre Riveline","doi":"10.1186/s12933-025-02789-3","DOIUrl":"10.1186/s12933-025-02789-3","url":null,"abstract":"<p><strong>Introduction & objectives: </strong>As in the general population, people living with type 1 diabetes (PWT1D) are faced with overweight and obesity, which contribute to cardiovascular (CV) risk. However, the role of visceral adiposity, due to its adverse metabolic profile, should also be addressed in PWT1D. We aimed to assess the 10-year CV risk of PWT1D according to body mass index (BMI) and waist-to-height ratio (WHtR), a parameter for estimating visceral adiposity.</p><p><strong>Methods: </strong>In this cross-sectional study, PWT1D in primary CV prevention from the SFDT1 cohort were categorized by BMI status, either normal (18.5-24.9 kg/m²) or overweight/obesity (≥ 25 kg/m²), and by WHtR according to the validated threshold of 0.5. The 10-year CV risk was estimated using the Steno Type 1 Risk Engine and classified into three categories: low (< 10%), intermediate (10-20%) and high (> 20%). The distribution of CV risk was assessed using density plots. In multivariable analysis, the association between BMI, WHtR, and high estimated 10-year CV risk was studied using spline regression models with sex stratification. Thresholds were determined by the Receiver Operating Characteristic (ROC) curve.</p><p><strong>Results: </strong>The study included 1,482 patients; 49.9% had a normal BMI, and 50.1% a BMI ≥ 25 kg/m². The proportion of patients with high CV risk was higher in PWT1D with overweight/obesity (12% vs. 7%) and in those with WHtR ≥ 0.5 (13% vs. 4%). BMI was significantly associated with high CV risk in men (p = 0.001) but a non-significant trend was found in women (p = 0.053). WHtR was significantly associated with high CV risk in both men (p < 0.001) and women (p = 0.046). The BMI threshold associated with high CV risk was 24.9 kg/m² for men, and the WHtR threshold was 0.5 for both men and women.</p><p><strong>Conclusion: </strong>In PWT1D in condition of primary CV prevention, visceral adiposity, assessed by WHtR, is a more robust marker of estimated 10-year CV risk than overweight/obesity status in both men and women.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"256"},"PeriodicalIF":8.5,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stress hyperglycemia ratio and the risk of new-onset chronic diseases: results of a national prospective longitudinal study.","authors":"Zhuang Ma, Lanlan Wu, Zheng Huang","doi":"10.1186/s12933-025-02810-9","DOIUrl":"10.1186/s12933-025-02810-9","url":null,"abstract":"<p><strong>Background: </strong>The stress hyperglycemia ratio (SHR), a dynamic biomarker of acute glucose dysregulation, has been established as a predictor of adverse acute outcomes. However, its longitudinal associations with chronic disease development, particularly in middle-aged and older populations, remain insufficiently characterized.</p><p><strong>Methods: </strong>This nationwide prospective cohort study analyzed data from 8942 adults aged ≥ 45 years in the China Health and Retirement Longitudinal Study (CHARLS). We established 14 disease-specific cohorts to the relationship between SHR and new-onset chronic conditions. Multivariable-adjusted Cox proportional hazards models with restricted cubic splines were utilized to estimate hazard ratios (HRs) per standard deviation (SD) increase in SHR, supported by comprehensive sensitivity analyses and subgroup stratifications.</p><p><strong>Results: </strong>Elevated SHR levels were significantly associated with increased risks of incident hypertension (HR = 1.30, 95% CI: 1.06-1.60; P < 0.001), dyslipidemia (HR = 1.43, 95% CI: 1.17-1.74; P < 0.001), diabetes (HR = 2.30, 95% CI: 1.82-2.91; P < 0.001), and liver disease (HR = 1.65, 95% CI: 1.21-2.26; P = 0.002). Conversely, elevated SHR levels correlated with a lower risk of lung disease (HR = 0.67, 95% CI: 0.50-0.89; P = 0.006). Restricted cubic spline analyses revealed a nonlinear relationship between SHR and diabetes risk (P-nonlinear = 0.02), while linear associations were observed for other outcomes. Subgroup analyses demonstrated consistency across demographic strata (P-interaction > 0.05).</p><p><strong>Conclusions: </strong>SHR demonstrates disease-specific associations with chronic disease development, indicating its potential value as a predictive marker for clinical risk assessment.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"251"},"PeriodicalIF":8.5,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide.","authors":"Zsombor I Hegedűs, Márk E Jakab, Tamás G Gergely, Nabil V Sayour, Andrea Kovács, Sára Antal, Tamás Kovács, Péter Ferdinandy, Zoltán V Varga, Viktória E Tóth","doi":"10.1186/s12933-025-02806-5","DOIUrl":"10.1186/s12933-025-02806-5","url":null,"abstract":"<p><strong>Background: </strong>Incretin analogues, used for the treatment of type 2 diabetes mellitus and obesity, such as GLP1-receptor agonist liraglutide (Lira) have been shown to reduce major adverse cardiac events in recent clinical trials of heart failure. Tirzepatide (TZP), a dual GIP/GLP1-receptor agonist has shown promising results in the SUMMIT trial as improved cardiovascular outcomes in patients with heart failure with preserved ejection fraction (HFpEF). However, data regarding their use in heart failure with reduced ejection fraction (HFrEF) is lacking. We performed a head-to-head comparative study in a mouse model of non-ischaemic cardiac injury induced by continuous angiotensin II (AngII) infusion, as AngII is a key driver of both heart failure forms.</p><p><strong>Methods: </strong>Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed. Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15). Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.</p><p><strong>Results: </strong>Mortality was significantly higher in AngII/Veh animals compared to controls, while AngII/TZP mice showed significantly reduced mortality after 14 days of treatment. Both Lira and TZP caused significant weight reduction compared to controls. AngII given alone also reduced body mass, and this reduction was further enhanced by TZP. Treatment with both compounds preserved cardiac systolic and diastolic function compared with AngII/Veh animals, as shown by normal ejection fraction and E/e', respectively. Both Lira and TZP decreased the AngII-induced elevation of cardiac fibrosis and hypertrophy markers, including Ctgf, Col1a1, Col3a1, and Nppa, while TZP also reduced the elevated Nppb level. TZP also reduced systemic inflammation, as shown by the reduction in serum CRP levels.</p><p><strong>Conclusions: </strong>Lira and TZP preserved cardiac function and decreased markers of hypertrophy and fibrosis in mice with AngII-induced heart failure, whereas TZP also significantly decreased mortality. In addition to HFpEF, the use of incretin analogues may also be of clinical relevance in the treatment of HFrEF. However, as patients with heart failure, AngII level is elevated and can cause weight loss/cachexia, the usage of incretin analogues to treat non-obese heart failure patients should be considered.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"253"},"PeriodicalIF":8.5,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel insights into beta cell ER stress CHOP and its role in HFpEF development.","authors":"Balaji Srinivas, Paula Fortuno, Hongmei Peng, Jiang Xu, Hamid Suhail, Hani N Sabbah, Nour-Eddine Rhaleb, Khalid Matrougui","doi":"10.1186/s12933-025-02703-x","DOIUrl":"10.1186/s12933-025-02703-x","url":null,"abstract":"<p><strong>Introduction: </strong>Heart failure with preserved ejection fraction (HFpEF) is a multifactorial cardiovascular disorder characterized by diastolic dysfunction and often associated with hypertension and metabolic disturbances. We aimed to determine the inter-relationship between C/EBP homologous protein (CHOP) in b-cells and HFpEF development.</p><p><strong>Methods: </strong>Eight-week-old male mice b-cell^flox/flox and b-cell^CHOP-/- were randomly divided into four groups: control b-cell^flox/flox and b-cell^CHOP-/- mice subjected to standard diet and water. b -cell^flox/flox and b-cell^CHOP-/- mice fed a high-fat diet (HFD) and L-NAME (0.5 g/L) for five weeks. A comprehensive cardiovascular, metabolic, and histological evaluation was conducted.</p><p><strong>Results: </strong>Following five weeks of HFD and L-NAME, b-cell^flox/flox mice exhibited clinical and molecular manifestations of HFpEF. These include diastolic dysfunction, a normal cardiac ejection fraction, hypertension, metabolic disorders, cardiac hypertrophy with fibrosis, pulmonary edema, renal injury, and reduced exercise tolerance. Vascular endothelial dysfunction was also observed. Western blot analysis showed a reduced phosphorylated endothelial nitric oxide synthase in mesenteric resistance arteries (MRA), concomitant with qRT-PCR data revealing elevated inflammatory and unfolded protein response markers in MRA, heart, and pancreas. Interestingly, b-cell^CHOP-/- mice subjected to an HFD and L-NAME were protected from HFpEF and its associated pathologies. These mice displayed improved cardiac and vascular endothelial function, exercise tolerance, and reduced unfolded protein response and inflammatory factors compared to their b-cell^flox/flox.</p><p><strong>Conclusion: </strong>Our research indicates that deleting the unfolded protein response CHOP in b-cells has a robust cardiovascular protective effect against HFpEF pathogenesis. Therefore, targeting CHOP in b-cells is a promising lead for HFpEF pathogenesis therapy.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"250"},"PeriodicalIF":8.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes.","authors":"Paola Giustina Simeone, Sarah Costantino, Rossella Liani, Romina Tripaldi, Augusto Di Castelnuovo, Armando Tartaro, Alessandro Mengozzi, Francesco Cosentino, Francesco Cipollone, Agostino Consoli, Francesco Paneni, Francesca Santilli","doi":"10.1186/s12933-025-02706-8","DOIUrl":"10.1186/s12933-025-02706-8","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major cardiovascular risk (CV) factor. Interleukin-1β (IL-1β), a cytokine involved in the pathogenesis of obesity-associated inflammation and type 2 diabetes (T2D), promotes hepatic steatosis. The Canakinumab Anti-inflammatory Thrombosis Outcome (CANTOS) trial showed that the inhibition of the IL-1β pathway was associated with a reduction of CV events in high-risk patients. The present study was designed to determine: (i) whether an equal degree of weight loss by liraglutide or lifestyle changes has a different impact on MASLD extent and IL-1β expression in peripheral blood mononuclear cells from obese subjects with prediabetes or early T2D; (ii) whether baseline IL-1β levels may predict the extent of weight loss and related metabolic changes.</p><p><strong>Methods: </strong>Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss. Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.</p><p><strong>Results: </strong>At baseline, IL-1β was positively correlated to body mass index (BMI), fasting plasma glucose, HbA1c, VAT, MASLD extent, platelet count, chemerin and interleukin-1 receptor antagonist (IL1-RA). After achievement of the weight loss target in the two groups, a significant but comparable reduction of IL-1β (p for difference = 0.56) was observed in both arms, in parallel with a comparable improvement in glycaemic control, C reactive protein (CRP), BMI and MASLD. Furthermore, basal IL-1β levels independently predicted the extent of MASLD decrease (p = 0.030); subjects in the highest tertile showed a median decrease of - 8.0 (95% CI - 12.3 to - 4.8) compared with - 23.0 (95% CI - 39.5 to - 16.3) in the lowest tertile.</p><p><strong>Conclusion: </strong>In patients with obesity with initial impairment of glucose metabolism successful weight loss is associated with a reduction of both IL-1β levels and MASLD degree. Of interest, basal levels of IL-1β predict the extent of MASLD improvement, regardless of the intervention. Our results may set the stage for ad-hoc studies investigating the usefulness of baseline IL-1β a level as a drug-response biomarker.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"247"},"PeriodicalIF":8.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12164075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vascular effects of perivascular adipose tissue-derived chemerin in obesity-associated cardiovascular disease.","authors":"Andy W C Man, Ning Xia, Huige Li","doi":"10.1186/s12933-025-02814-5","DOIUrl":"10.1186/s12933-025-02814-5","url":null,"abstract":"<p><p>Perivascular adipose tissue (PVAT) is a unique and metabolically active adipose tissue that is adjacent to most systemic blood vessels. Healthy PVAT exerts anticontractile and anti-inflammatory effects, contributing to vascular protection. However, during obesity, PVAT becomes proinflammatory and profibrotic, exacerbating vascular dysfunction. Chemerin, a multifunctional adipokine, has emerged as a key regulator of vascular tone, inflammation, and remodeling. Although liver-derived chemerin dominates the circulating chemerin pool, PVAT-derived chemerin plays a more localized and functionally important role in vascular pathophysiology because of its proximity to the vessel wall. This review highlights the role of PVAT-derived chemerin in vascular health, the mechanistic involvement of PVAT-derived chemerin in certain aspects of obesity-associated cardiovascular diseases, and the therapeutic potential of targeting PVAT-derived chemerin.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"249"},"PeriodicalIF":8.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12164128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cumulative exposures to glycaemia and lipids are associated with coronary artery disease in type 1 diabetes: a call for action.","authors":"Rebecka Bergdal, Valma Harjutsalo, Per-Henrik Groop, Stefan Mutter","doi":"10.1186/s12933-025-02803-8","DOIUrl":"10.1186/s12933-025-02803-8","url":null,"abstract":"<p><strong>Background: </strong>Hyperglycaemia and dyslipidaemia are well-known risk factors for coronary artery disease (CAD) in type 1 diabetes. The impact of long-term cumulative exposure to these risk factors is less explored. We investigated the relationship between cumulative glycaemic and lipid exposure and CAD in individuals with type 1 diabetes.</p><p><strong>Methods: </strong>This longitudinal study included 3495 adults with type 1 diabetes from the FinnDiane cohort, without end-stage kidney disease and no history of CAD or stroke at the study baseline. Total cumulative glycaemic exposure (CGE_tot) and cumulative hyperglycaemic exposure (CGE_hg), accounting only for time spent above an HbA_1c of 53 mmol/mol (7%), were calculated from diabetes diagnosis.</p><p><strong>Results: </strong>During a median follow-up of 19.38 years, 534 participants had their first-ever CAD event. CGE_hg (odds ratio 1.03 [95% CI 1.02-1.05], p < 0.001) and cumulative exposure to LDL cholesterol, triglycerides, and non-HDL cholesterol all significantly increased the odds for incident CAD. The highest tertile of CGE_hg associated with a twofold odds increase for incident CAD. CGE_tot was not significantly associated with CAD after adjusting for cumulative lipid exposure.</p><p><strong>Conclusions: </strong>Both hyperglycaemia and dyslipidaemia are independently associated with CAD in type 1 diabetes. These findings emphasize the importance of reaching an HbA_1c below 53 mmol/mol (7%) and minimizing lipid exposure, as well as calling on health care professionals to not settle for suboptimal care, but to continue their support and encouragement towards better management of diabetes.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"248"},"PeriodicalIF":8.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12164207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Association of non-insulin-based insulin resistance indices with disease severity and adverse outcome in idiopathic pulmonary arterial hypertension: a multi-center cohort study.","authors":"Sicheng Zhang, Luyang Gao, Sicong Li, Manqing Luo, Lichuan Chen, Qunying Xi, Zhihui Zhao, Qing Zhao, Tao Yang, Qixian Zeng, Xin Li, Zhihua Huang, Anqi Duan, Yijia Wang, Qin Luo, Yansong Guo, Zhihong Liu","doi":"10.1186/s12933-025-02792-8","DOIUrl":"10.1186/s12933-025-02792-8","url":null,"abstract":"","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"245"},"PeriodicalIF":8.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing trajectories of diabetes-related health parameters before diabetes diagnosis in diabetes subtypes: analysis of a 20-year long prospective cohort study in Sweden.","authors":"Tatjana P Liedtke, Eike A Strathmann, Emma Ahlqvist, Olof Asplund, Charlena S Penz, Paula Stürmer, Cara Övermöhle, Anton Lager, Boel Brynedal, Hrafnhildur Gudjonsdottir, Wolfgang Lieb, Katharina S Weber","doi":"10.1186/s12933-025-02786-6","DOIUrl":"10.1186/s12933-025-02786-6","url":null,"abstract":"<p><strong>Background: </strong>Evidence is limited on whether alterations in diabetes-related health parameters are detectable before clinical diagnosis in novel diabetes subtypes. We investigated trajectories of diabetes-related health parameters in individuals with recently diagnosed type 2 diabetes (T2D).</p><p><strong>Methods: </strong>Using data from the Stockholm Diabetes Prevention Programme cohort (SDPP) participants (n = 215) with recent onset T2D were classified as having severe insulin-deficient diabetes (SIDD, 9%), severe insulin-resistant diabetes (SIRD, 15%), mild obesity-related diabetes (MOD, 14%) and mild age-related diabetes (MARD, 62%). Participants without a family history of diabetes who remained diabetes-free throughout the study served as the controls (n = 2531). Multilevel longitudinal mixed-effects models were used to analyse the trajectories of fasting plasma glucose (FPG) and insulin, body mass index (BMI), homeostasis model assessment estimates of beta-cell function (HOMA2-B) and insulin resistance (HOMA2-IR), waist-to hip-ratio (WHR), diastolic blood pressure (DBP) and systolic blood pressure (SBP) up to 20 years before and 10 years after T2D diagnosis. Pairwise comparisons of the estimated marginal means were used to assess differences between all groups.</p><p><strong>Results: </strong>Individuals with SIDD consistently exhibited the highest FPG concentrations (P < 0.001) and the steepest decline in HOMA2-B levels among all subtypes. BMI was higher in MOD and SIRD than in SIDD and MARD throughout the study period (P < 0.01). Individuals with SIRD showed the highest fasting insulin concentrations and higher HOMA2-IR than those with MOD and MARD (P < 0.001). WHR and DBP were comparable between subgroups, while SIDD had higher SBP than MOD (P = 0.03). The control group exhibited the mildest trajectories across all parameters except for HOMA2-B. Notably, these changes were visible up to 20 years prior to diagnosis.</p><p><strong>Conclusions: </strong>In a Swedish population, trajectories of diabetes-related health parameters differed up to 20 years before diagnosis between the T2D-related subtypes and controls. This might support early prediction of subtype-specific risks for long-term complications, allowing early initiation of personalized treatment strategies.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"244"},"PeriodicalIF":8.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Association between triglyceride-glucose index and mortality in critically ill patients with atrial fibrillation: a retrospective cohort study.","authors":"Rong Ding, Erjing Cheng, Miao Wei, Liya Pan, Lu Ye, Yi Han, Xuan Zhang, Chao Xue, Jiannan Gong, Hui Zhao","doi":"10.1186/s12933-025-02787-5","DOIUrl":"10.1186/s12933-025-02787-5","url":null,"abstract":"","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"246"},"PeriodicalIF":8.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}